<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-8-5</article-id><article-id pub-id-type="pmid">17319955</article-id><article-id pub-id-type="doi">10.1186/1471-2350-8-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Resequencing of genes for transforming growth factor &#x003b2;1 (<italic>TGFB1</italic>) type 1 and 2 receptors (<italic>TGFBR1</italic>, <italic>TGFBR2</italic>), and association analysis of variants with diabetic nephropathy</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>McKnight</surname><given-names>Amy Jayne</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>a.j.mcknight@lineone.net</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Savage</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>d.savage@qub.ac.uk</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Patterson</surname><given-names>Chris C</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>c.patterson@qub.ac.uk</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Sadlier</surname><given-names>Denise</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>DSADLIER@partners.org</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Maxwell</surname><given-names>A Peter</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>a.p.maxwell@qub.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Nephrology Research Group, Queen's University of Belfast, Belfast, UK</aff><aff id="I2"><label>2</label>Epidemiology Research Groups, Queen's University of Belfast, Belfast, UK</aff><aff id="I3"><label>3</label>Faculty of Life Sciences, University of Manchester, Manchester, UK</aff><aff id="I4"><label>4</label>Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>23</day><month>2</month><year>2007</year></pub-date><volume>8</volume><fpage>5</fpage><lpage>5</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/5"/><history><date date-type="received"><day>3</day><month>8</month><year>2006</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 McKnight et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>McKnight et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> McKnight Jayne Amy a.j.mcknight@lineone.net </dc:author><dc:title> Resequencing of genes for transforming growth factor &#x003b2;1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 8(1): 5-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2007)8:1&#x0003c;5&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Diabetic nephropathy is the leading cause of end stage renal failure in the western world. There is substantial epidemiological evidence supporting a genetic predisposition to diabetic nephropathy, however the exact molecular mechanisms remain unknown. Transforming growth factor (TGF&#x003b2;1) is a crucial mediator in the pathogenesis of diabetic nephropathy.</p></sec><sec sec-type="methods"><title>Methods</title><p>We investigated the role of five known single nucleotide polymorphisms (SNPs) in the <italic>TGFB1 </italic>gene for their association with diabetic nephropathy in an Irish, type 1 diabetic case (n = 272) control (n = 367) collection. The activity of TGF&#x003b2;1 is facilitated by the action of type 1 and type 2 receptors, with both receptor genes (<italic>TGFBR1 </italic>and <italic>TGFBR2</italic>) shown to be upregulated in diabetic kidney disease. We therefore screened <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes for genomic variants using WAVE&#x02122; (dHPLC) technology and confirmed variants by direct capillary sequencing. Allele frequencies were determined in forty-eight healthy individuals. Data for all SNPs was assessed for Hardy Weinberg equilibrium, with genotypes and allele frequencies compared using the &#x003c7;<sup>2 </sup>test for contingency tables. Patterns of linkage disequilibrium were established and common haplotypes estimated.</p></sec><sec><title>Results</title><p>Fifteen variants were identified in these genes, seven of which are novel, and putatively functional SNPs were subsequently genotyped using TaqMan&#x02122;, Invader&#x02122; or Pyrosequencing<sup>&#x000ae; </sup>technology. No significant differences (<italic>p </italic>&#x0003e; 0.1) were found in genotype or allele distributions between cases and controls for any of the SNPs assessed.</p></sec><sec><title>Conclusion</title><p>Our results suggest common variants in <italic>TGFB1</italic>, <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes do not strongly influence genetic susceptibility to diabetic nephropathy in an Irish Caucasian population.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Diabetic nephropathy is a major clinical complication of diabetes mellitus. Epidemiological evidence supporting a genetic contribution to this disease includes ethnicity differences [<xref ref-type="bibr" rid="B1">1</xref>], familial clustering [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>] and the fact that only a subset of individuals with type 1 diabetes develops diabetic nephropathy regardless of metabolic control [<xref ref-type="bibr" rid="B4">4</xref>]. In addition, simulation studies have shown that environmental effects are insufficient to account for the familial aggregation of this disease [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Transforming growth factor beta (TGF&#x003b2;1) is a multifunctional cytokine implicated in the pathogenesis of many forms of progressive renal disease, including diabetic nephropathy, by promoting renal hypertrophy and the accumulation of extracellular matrix [<xref ref-type="bibr" rid="B6">6</xref>]. Protein and mRNA levels of TGF&#x003b2;1 are significantly increased in the renal glomeruli and tubulointerstitium of animal models of diabetes and in humans with diabetes [<xref ref-type="bibr" rid="B7">7</xref>]. TGF&#x003b2;1 is transcriptionally activated by high extracellular glucose in murine glomerular mesangial cells [<xref ref-type="bibr" rid="B8">8</xref>]. Transgenic mice over-expressing TGF&#x003b2;1 develop progressive renal failure, suggesting that chronically elevated levels of circulating TGF&#x003b2;1 are integral to the pathogenesis of kidney disease [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Direct blockade of TGF&#x003b2; protein by chronic administration of anti-TGF&#x003b2;1 antibodies has been shown to decrease renal insufficiency [<xref ref-type="bibr" rid="B11">11</xref>]. In addition, antisense TGF&#x003b2;1 oligonucleotides reduce the cellular hypertrophy and stimulation of matrix synthesis normally seen in renal cells exposed to high extracellular glucose [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The activity of TGF&#x003b2;1 in regulating cell proliferation, differentiation and extracellular matrix production are mediated by a heterodimeric complex of type 1 and type 2 receptors. Upregulation of TGF&#x003b2;1 receptors have been reported in animal models of glomerulosclerosis [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. It has been proposed that upregulation of TGF&#x003b2;R2 induced by high extracellular glucose may contribute to distal tubular hypertrophy in diabetic nephropathy [<xref ref-type="bibr" rid="B15">15</xref>]. Isono and colleagues demonstrated that increased expression of TGF&#x003b2;R2 in the diabetic kidney is primarily due to stimulation of gene transcription rather than increased mRNA stability [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>TGF&#x003b2;1 is encoded by the <italic>TGFB1 </italic>gene located at chromosome 19q13.1 [<xref ref-type="bibr" rid="B17">17</xref>]. We have investigated the role of five known single nucleotide polymorphisms, which may influence <italic>TGFB1 </italic>gene expression (<italic>TGFB1</italic>: -800G&#x0003e;A, -509C&#x0003e;T, +72InsC, +869T&#x0003e;C, +915G&#x0003e;C) for their association with diabetic nephropathy. TGF&#x003b2; receptors type 1 and type 2 are encoded by <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes respectively. At present there are over six hundred variants recorded in dbSNP for these genes, with little information available on the role of these variants in relation to renal complications of diabetes. We have screened the genomic draft sequence for the <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes in an Irish population to identify genomic variants. Allele frequencies were subsequently determined in a healthy control population and selected SNPs genotyped in a case-control collection. In summary, we investigated if putatively functional variants in three genes, <italic>TGFB1, TGFBR1 and TGFBR2</italic>, contribute to genetic susceptibility to diabetic nephropathy in type 1 diabetes.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>Ethical approval was obtained from the appropriate Research Ethics Committees in each country and written, informed consent obtained from individuals prior to conducting this study. The case and control groups used for this study (Table <xref ref-type="table" rid="T1">1</xref>) have been described previously [<xref ref-type="bibr" rid="B18">18</xref>]. All patients were at least third generation Irish Caucasians diagnosed with type 1 diabetes mellitus before 31 years of age, and required insulin from diagnosis. Patients with nephropathy (cases, n = 272) had diabetes for at least 10 years before the onset of proteinuria (&#x0003e;0.5 g/24 h). Patients without nephropathy (controls, n = 367) had diabetes for at least 15 years, were not in receipt of antihypertensive medication, and had no evidence of non-diabetic renal disease. Patients with microalbuminuria were excluded from both groups.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics of cases (n = 272) and controls (n = 367) (Data are n, mean &#x000b1; SD)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Criteria</bold></td><td align="center"><bold>Cases</bold></td><td align="center"><bold>Controls</bold></td></tr></thead><tbody><tr><td align="left"><bold>N</bold></td><td align="center">272</td><td align="center">367</td></tr><tr><td align="left"><bold>Gender</bold></td><td></td><td></td></tr><tr><td align="left">Male</td><td align="center">61.4 %</td><td align="center">40.3 %</td></tr><tr><td align="left">Female</td><td align="center">38.6 %</td><td align="center">59.7 %</td></tr><tr><td align="left"><bold>Age at Diagnosis </bold>(years)</td><td align="center">17.1 &#x000b1; 8.2</td><td align="center">16.8 &#x000b1; 8.1</td></tr><tr><td align="left"><bold>*Duration of Diabetes </bold>(years)</td><td align="center">26.9 &#x000b1; 8.3</td><td align="center">27.7 &#x000b1; 9.0</td></tr><tr><td align="left"><bold>HbA1</bold><sub><bold>C </bold></sub>(%)</td><td align="center">8.5 &#x000b1; 1.7</td><td align="center">8.4 &#x000b1; 1.6</td></tr><tr><td align="left"><bold>BMI </bold>(kg/m<sup>2</sup>)</td><td align="center">26.0 &#x000b1; 3.8</td><td align="center">26.2 &#x000b1; 3.5</td></tr><tr><td align="left"><bold>Systolic Blood Pressure </bold>(mm Hg)</td><td align="center">150.1 &#x000b1; 22.6</td><td align="center">126.9 &#x000b1; 16.6</td></tr><tr><td align="left"><bold>Diastolic Blood Pressure </bold>(mm Hg)</td><td align="center">86.5 &#x000b1; 11.4</td><td align="center">76.1 &#x000b1; 7.3</td></tr></tbody></table><table-wrap-foot><p>* Duration of diabetes was calculated from the date of diagnosis of diabetes to date of recruitment</p><p>* BMI = body mass index</p></table-wrap-foot></table-wrap></sec><sec><title><italic>In silico </italic>analysis</title><p>For <italic>TGFBR1</italic>, the nucleotide sequence of draft clone RP11-96L7 for human chromosome 9 was downloaded from the National Centre for Biotechnology Information [<xref ref-type="bibr" rid="B19">19</xref>]. Similarly, the sequence for <italic>TGFBR2 </italic>was obtained for draft clone RP11-1024P17 on human chromosome 3. Reference mRNA (NM_004612; NM_003242) and protein (NP_004603; NP_003233) sequences were also downloaded from NCBI for <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>respectively. These were used to determine intron-exon boundaries for genomic DNA using Vector NTI Advance (suite 2, version 8, Informax Inc (Europe), Oxford, UK). The nomenclature for all identified variants follows the Human Genome Variation Society recommendations for coding sequences, updated 21<sup>st </sup>May 2005 [<xref ref-type="bibr" rid="B20">20</xref>]. In addition, we have provided rs numbers for all previously identified SNPs and ss numbers for novel SNPs to facilitate ease of comparison between research groups.</p></sec><sec><title>Amplification and mutation screening</title><p>6464 bases of <italic>TGFBR1 </italic>and 5204 bases of <italic>TGFBR2 </italic>genomic sequences were divided into fragments with an average size of approximately 500 base pairs, for PCR and screening purposes in 15 case and 15 control individuals. As the <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>gene sequences cover approximately 45 kb and 84 kb respectively from start to stop codon, only the coding regions of these genes (including all exons, exon-intron boundaries and untranslated regions) were screened to prioritise the identification of potentially functional gene variants. Each PCR product was then evaluated using WaveMaker v3.4 software (Transgenomic Ltd, Crewe, UK) and analysed on the WAVE&#x02122; (dHPLC) DNA Fragment Analysis System (Transgenomic Ltd) following the manufacturer's recommendations. Differentially separating fragments (representing DNA variants) were bidirectionally sequenced to identify variants using an ABI PRISM<sup>&#x000ae; </sup>3100 Genetic Analyser (Applied Biosystems, Warrington, UK). Forty-eight healthy controls (n = 96 chromosomes) from the Young Hearts collection [<xref ref-type="bibr" rid="B21">21</xref>] (a healthy Irish Caucasian population) were genotyped by direct capillary sequencing (Applied Biosystems) to establish allele frequencies for all gene variants.</p></sec><sec><title>Genotyping</title><p>Five SNPs were selected for genotyping in the TGFB1 gene as they have been previously suggested to influence the expression of TGF&#x003b2;1, in addition to demonstrating a minor allele frequency greater than 5%. TaqMan assays were successfully designed for <italic>TGFB1: </italic>-800G&#x0003e;A (rs1800468), <italic>TGFB1: </italic>-509C&#x0003e;T (rs1800469), <italic>TGFB1: </italic>+869T&#x0003e;C (rs1982073) and <italic>TGFB1: </italic>+915G&#x0003e;C (rs1800471) SNPs, but proved problematic for <italic>TGFB1: </italic>+72InsC (rs1800999) due to the presence of a long C homopolymer. <italic>TGFB1: </italic>+72InsC was successfully genotyped using a biplex Invader&#x02122; assay (Third WAVE Technologies Inc, Madison, MI, USA). Genotyping was performed for receptor variants using Pyrosequencing<sup>&#x000ae; </sup>technology according to the manufacturer's instructions (Biotage, Uppsala, Sweden). Details of the primer sequences used for resequencing purposes, together with the WAVE conditions and the oligos used for the genotyping assays are listed (Tables <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>, <xref ref-type="table" rid="T5">5</xref>) with further details readily available from the authors on request. 272 case and 367 control samples were available for genotyping <italic>TGFB1 </italic>SNPs, however fewer samples were available (241 cases and 322 controls) for genotyping <italic>TGFBR2 </italic>gene variants. Genotype frequencies were assessed for Hardy-Weinberg equilibrium using a &#x003c7;<sup>2 </sup>goodness-of-fit test. The &#x003c7;<sup>2 </sup>test for contingency tables was used to compare genotype and allele frequencies between case and control subjects with the level of significance set to p &#x0003c; 0.05. Haploview [<xref ref-type="bibr" rid="B22">22</xref>] was used to visualise linkage disequilibrium (LD) and haplotype blocks within each gene.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Primer sequences used for screening <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><italic>Primer Set</italic></bold></td><td align="left">Primer 1</td><td align="left">Primer 2</td></tr></thead><tbody><tr><td align="left"><bold><italic>TGFBR1 </italic>i</bold></td><td align="left">tcctccttaaaaggttctgc</td><td align="left">agaaagtcctcagatcccag</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>ii</bold></td><td align="left">ggaggctatttgggggtgt</td><td align="left">gcgagcgccggtttctg</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>iii</bold></td><td align="left">actcacacagacacaccca</td><td align="left">aagagcaggagcgagccag</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>iv</bold></td><td align="left">ctaagagcaacaaacagtgc</td><td align="left">gtcacttcttgcctctaaacg</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>v</bold></td><td align="left">tgcaggaattgtgtaggattg</td><td align="left">tggagctgacttattgattcg</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>vi</bold></td><td align="left">ctccccagtgagataaattc</td><td align="left">aatcttgaagaagttcctag</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>vii</bold></td><td align="left">gcttactctgaggaactaaag</td><td align="left">agatgcggttttgtcatgttg</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>viii</bold></td><td align="left">aagtattgtaggtcatgtgg</td><td align="left">gatattttctggaagggcaac</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>ix</bold></td><td align="left">gtctgaaaggaggttcatc</td><td align="left">caggaagagaatacactagg</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>x</bold></td><td align="left">gtgatcttttaatgccttgg</td><td align="left">aacattggtttgactgcta</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>xi</bold></td><td align="left">caccagtaccctattgatgg</td><td align="left">aaggagagttcaggcaaagc</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>xii</bold></td><td align="left">gcaactcagtcaacaggaag</td><td align="left">gaatcaaggaaactctagtgg</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>xiii</bold></td><td align="left">agaaagtgatttactcct g</td><td align="left">attcaaacatgaccatgc</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>xiv</bold></td><td align="left">ctttctcctaccaaaatgtgc</td><td align="left">ctgaattaaaagctgccttcc</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>i</bold></td><td align="left">cctcctggctggcgagcg</td><td align="left">ggaccaaacgtgccccgc</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>ii</bold></td><td align="left">aagcaaatggctactcaacc</td><td align="left">acacatacatgcagagaacacc</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>iii</bold></td><td align="left">tgcgaatgctggagaacagg</td><td align="left">ggaggacaccacctaacgtatg</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>iv</bold></td><td align="left">agctgaagtttgaaggaagagc</td><td align="left">gcacacggttgttgtagttggt</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>v</bold></td><td align="left">catcatcttctactgctaccgc</td><td align="left">ggttcccgttggatgtcctcat</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>vi</bold></td><td align="left">ggagttggggaaacaatactgg</td><td align="left">gggtcaagtcgtgtaaaaaagg</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>vii</bold></td><td align="left">ctatctgtacctttctgtgc</td><td align="left">ccaatacgatttgtcggatc</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>viii</bold></td><td align="left">gttacttagtgcttcatgctcc</td><td align="left">ccttccagggtaacacaagata</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>ix</bold></td><td align="left">gtgttgggagtgttagtgtacc</td><td align="left">ccgtaggtctaccacacactct</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>x</bold></td><td align="left">accaactcatggtgccctttgg</td><td align="left">cggtatggaacttttctctg</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>xi</bold></td><td align="left">gctgtgttagcacttcctcagg</td><td align="left">ggtttagaccccccgatcaaat</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>xii</bold></td><td align="left">tgtttgaggaccagtgttcccg</td><td align="left">ccgaggactaacgagttcgtgt</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>WAVE conditions used for screening <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Primer Set</bold></td><td align="center"><bold>Tm&#x000b0;C</bold></td><td align="center"><bold>Melt Range&#x000b0;C</bold></td><td align="center"><bold>Run Temperature&#x000b0;C</bold></td><td align="center"><bold>WAVE Buffer B (%)</bold></td></tr></thead><tbody><tr><td align="left"><bold><italic>TGFBR1 </italic>i</bold></td><td align="center">59.4</td><td align="center">54 &#x02013; 72</td><td align="center">57</td><td align="center">69&#x02013;79</td></tr><tr><td></td><td></td><td></td><td align="center">59</td><td align="center">67&#x02013;77</td></tr><tr><td></td><td></td><td></td><td align="center">64</td><td align="center">62&#x02013;64</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>ii</bold></td><td align="center">63.3</td><td align="center">60 &#x02013; 72</td><td align="center">63</td><td align="center">68&#x02013;78</td></tr><tr><td></td><td></td><td></td><td align="center">69</td><td align="center">62&#x02013;72</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>iii</bold></td><td align="center">69.2</td><td align="center">58 &#x02013; 75</td><td align="center">69</td><td align="center">68&#x02013;78</td></tr><tr><td></td><td></td><td></td><td align="center">72</td><td align="center">65&#x02013;75</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>iv</bold></td><td align="center">55.9</td><td align="center">54 &#x02013; 65</td><td align="center">55</td><td align="center">68&#x02013;78</td></tr><tr><td></td><td></td><td></td><td align="center">59</td><td align="center">64&#x02013;74</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>v</bold></td><td align="center">57.2</td><td align="center">54 &#x02013; 65</td><td align="center">55</td><td align="center">62&#x02013;72</td></tr><tr><td></td><td></td><td></td><td align="center">59</td><td align="center">58&#x02013;68</td></tr><tr><td></td><td></td><td></td><td align="center">61</td><td align="center">56&#x02013;58</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>vi</bold></td><td align="center">56.1</td><td align="center">54 &#x02013; 65</td><td align="center">56</td><td align="center">68&#x02013;78</td></tr><tr><td></td><td></td><td></td><td align="center">59</td><td align="center">65&#x02013;75</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>vii</bold></td><td align="center">56.5</td><td align="center">54 &#x02013; 68</td><td align="center">55</td><td align="center">69&#x02013;79</td></tr><tr><td></td><td></td><td></td><td align="center">58</td><td align="center">66&#x02013;76</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>viii</bold></td><td align="center">57.0</td><td align="center">54 &#x02013; 65</td><td align="center">57</td><td align="center">67&#x02013;77</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>ix</bold></td><td align="center">57.4</td><td align="center">55 &#x02013; 67</td><td align="center">56</td><td align="center">67&#x02013;77</td></tr><tr><td></td><td></td><td></td><td align="center">58</td><td align="center">64&#x02013;75</td></tr><tr><td></td><td></td><td></td><td align="center">62</td><td align="center">61&#x02013;71</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>x</bold></td><td align="center">54.8</td><td align="center">51 &#x02013; 66</td><td align="center">54</td><td align="center">65&#x02013;75</td></tr><tr><td></td><td></td><td></td><td align="center">57</td><td align="center">62&#x02013;72</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>xi</bold></td><td align="center">54.6</td><td align="center">54 &#x02013; 67</td><td align="center">54</td><td align="center">65&#x02013;75</td></tr><tr><td></td><td></td><td></td><td align="center">58</td><td align="center">60&#x02013;70</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>xii</bold></td><td align="center">56.9</td><td align="center">55 &#x02013; 65</td><td align="center">56</td><td align="center">64&#x02013;77</td></tr><tr><td></td><td></td><td></td><td align="center">58</td><td align="center">62&#x02013;72</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>xiii</bold></td><td align="center">55.8</td><td align="center">52 &#x02013; 62</td><td align="center">56</td><td align="center">67&#x02013;77</td></tr><tr><td align="left"><bold><italic>TGFBR1 </italic>xiv</bold></td><td align="center">55.2</td><td align="center">54 &#x02013; 63</td><td align="center">55</td><td align="center">67&#x02013;77</td></tr><tr><td></td><td></td><td></td><td align="center">59</td><td align="center">63&#x02013;73</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>i</bold></td><td align="center">66.1</td><td align="center">59&#x02013;74</td><td align="center">60</td><td align="center">63&#x02013;73</td></tr><tr><td></td><td></td><td></td><td align="center">65</td><td align="center">58&#x02013;68</td></tr><tr><td></td><td></td><td></td><td align="center">67</td><td align="center">56&#x02013;66</td></tr><tr><td></td><td></td><td></td><td align="center">70</td><td align="center">53&#x02013;63</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>ii</bold></td><td align="center">66.3</td><td align="center">61 &#x02013; 72</td><td align="center">64</td><td align="center">58&#x02013;68</td></tr><tr><td></td><td></td><td></td><td align="center">66</td><td align="center">56&#x02013;66</td></tr><tr><td></td><td></td><td></td><td align="center">69</td><td align="center">52&#x02013;62</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>iii</bold></td><td align="center">58.5</td><td align="center">57 &#x02013; 61</td><td align="center">59</td><td align="center">61&#x02013;71</td></tr><tr><td></td><td></td><td></td><td align="center">61</td><td align="center">59&#x02013;69</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>iv</bold></td><td align="center">59.8</td><td align="center">55 &#x02013; 65</td><td align="center">56</td><td align="center">67&#x02013;77</td></tr><tr><td></td><td></td><td></td><td align="center">61</td><td align="center">60&#x02013;70</td></tr><tr><td></td><td></td><td></td><td align="center">63</td><td align="center">58&#x02013;68</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>v</bold></td><td align="center">60.5</td><td align="center">57&#x02013;64</td><td align="center">62</td><td align="center">58&#x02013;68</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>vi</bold></td><td align="center">63.5</td><td align="center">62&#x02013;65</td><td align="center">64</td><td align="center">55&#x02013;65</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>vii</bold></td><td align="center">59.7</td><td align="center">53&#x02013;71</td><td align="center">59</td><td align="center">57&#x02013;67</td></tr><tr><td></td><td></td><td></td><td align="center">61</td><td align="center">52&#x02013;62</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>viii</bold></td><td align="center">59.7</td><td align="center">53 &#x02013; 71</td><td align="center">59</td><td align="center">66&#x02013;76</td></tr><tr><td></td><td></td><td></td><td align="center">61</td><td align="center">64&#x02013;74</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>ix</bold></td><td align="center">61.0</td><td align="center">60&#x02013;61</td><td align="center">61</td><td align="center">57&#x02013;67</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>x</bold></td><td align="center">57.0</td><td align="center">51&#x02013;66</td><td align="center">52</td><td align="center">63&#x02013;73</td></tr><tr><td></td><td></td><td></td><td align="center">58</td><td align="center">57&#x02013;67</td></tr><tr><td></td><td></td><td></td><td align="center">62</td><td align="center">53&#x02013;63</td></tr><tr><td></td><td></td><td></td><td align="center">64</td><td align="center">50&#x02013;60</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>xi</bold></td><td align="center">54.4</td><td align="center">53 &#x02013; 66</td><td align="center">54</td><td align="center">67&#x02013;77</td></tr><tr><td></td><td></td><td></td><td align="center">56</td><td align="center">65&#x02013;75</td></tr><tr><td></td><td></td><td></td><td align="center">60</td><td align="center">61&#x02013;71</td></tr><tr><td align="left"><bold><italic>TGFBR2 </italic>xii</bold></td><td align="center">57.0</td><td align="center">56&#x02013;60</td><td align="center">59</td><td align="center">63&#x02013;73</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>TaqMan primers, probes, quencher and annealing temperature for relevant assays.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Primer set</bold></td><td align="center"><bold>Primer 1</bold></td><td align="center"><bold>Primer 2</bold></td><td align="center"><bold>FAM&#x02122; Labelled Probe</bold></td><td align="center"><bold>Vic&#x02122; Labelled Probe</bold></td><td align="center"><bold>Fluorescent Quencher</bold></td><td align="center"><bold>Anneal </bold>(1 minute)</td></tr></thead><tbody><tr><td align="center"><italic>TGFB1 </italic>-800G&#x0003e;A</td><td align="center">gctatcgcctgcacacagc</td><td align="center">aggacagaagcggtcccat</td><td align="center">tgcctccaacgtcaccaccatc</td><td align="center">tctgcctccaacatcaccaccatc</td><td align="center">TAMRA</td><td align="center">62&#x000b0;C</td></tr><tr><td align="center"><italic>TGFB1 </italic>-509C&#x0003e;T</td><td align="center">ttagccacatgggaggtgct</td><td align="center">ccaggcggagaaggcttaa</td><td align="center">acccttccatccctcaggtgtcct</td><td align="center">ccctcccatccttcaggtgtcctg</td><td align="center">TAMRA</td><td align="center">62&#x000b0;C</td></tr><tr><td align="center"><italic>TGFB1 </italic>+869T&#x0003e;C</td><td align="center">caccacaccagccctgttc</td><td align="center">ccaggcgtcagcaccagta</td><td align="center">agcagcggcagca</td><td align="center">cagcagcagcagc</td><td align="center">None</td><td align="center">60&#x000b0;C</td></tr><tr><td align="center"><italic>TGFB1 </italic>+915G&#x0003e;C</td><td align="center" colspan="4">Developed by Applied Biosystems (USA) as a Research and Development Kit</td><td align="center">None</td><td align="center">56&#x000b0;C</td></tr></tbody></table><table-wrap-foot><p><italic>TGFBR1</italic>+72InsC was genotyped by a commercial Invader kit designed and manufactured by Third WAVE technologies (Madison, MI, USA)</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Pyrosequencing primers, dispensation order and sequence to analyse for relevant assays</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Primer Set</bold></td><td align="center"><bold>Forward Primer</bold></td><td align="center"><bold>Reverse Primer</bold></td><td align="center"><bold>Sequence Primer</bold></td><td align="center"><bold>Dispensation order</bold></td><td align="center"><bold>Sequence to Analyse</bold></td></tr></thead><tbody><tr><td align="center">TGFBR2 c.*747C&#x0003e;G</td><td align="center">tcctgtgtgcccttatttctc</td><td align="center">tgaaggtaaaaagtggggttc</td><td align="center">agtttctaaactaggttgag</td><td align="center">tcgagagtctac</td><td align="center">c/ggagagtttctaaac</td></tr><tr><td align="center">TGFBR2 c.1149G&#x0003e;A</td><td align="center">gatcacactccatgtggg</td><td align="center">ccagacgcagggaaagc</td><td align="center">agagctccaatatcctc</td><td align="center">tgatgagacgac tac</td><td align="center">g/atgaagaacgacctaacc</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Results</title><p>We have submitted our annotated sequencing data for <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes as GenBank accession numbers <ext-link ext-link-type="gen" xlink:href="DQ383416">DQ383416</ext-link> &#x02013; <ext-link ext-link-type="gen" xlink:href="DQ383424">DQ383424</ext-link> and <ext-link ext-link-type="gen" xlink:href="DQ377553">DQ377553</ext-link> &#x02013; <ext-link ext-link-type="gen" xlink:href="DQ377559">DQ377559</ext-link> respectively. A total of fifteen variants were identified in these genes (<italic>TGFBR1</italic>, n = 5; <italic>TGFBR2</italic>, n = 10) of which eight were previously recorded in dbSNP; we have obtained unique NCBI identifiers for all novel SNPs (n = 7; Table <xref ref-type="table" rid="T6">6</xref>).</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Minor allele frequencies of identified variants in <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes, based on genotyping of 48 healthy control individuals. Accepted GenBank accession numbers for the reference sequences describing <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>gene variants are <ext-link ext-link-type="gen" xlink:href="DQ383416">DQ383416</ext-link> &#x02013; <ext-link ext-link-type="gen" xlink:href="DQ383424">DQ383424</ext-link> and <ext-link ext-link-type="gen" xlink:href="DQ377553">DQ377553</ext-link> &#x02013; <ext-link ext-link-type="gen" xlink:href="DQ37759">DQ37759</ext-link> respectively.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Variant</bold></td><td align="center"><bold>Unique NCBI Identifier</bold></td><td align="center"><bold>Minor Allele Frequency (%)</bold></td></tr></thead><tbody><tr><td align="left"><sup><italic>a</italic></sup><italic>TGFBR1</italic>: c.694A&#x0003e;C</td><td align="center">ss50394789</td><td align="center">4.3</td></tr><tr><td align="left"><sup><italic>a</italic></sup><italic>TGFBR1</italic>: c.*899T&#x0003e;C</td><td align="center">ss50394790</td><td align="center">2.2</td></tr><tr><td align="left"><sup><italic>a</italic></sup><italic>TGFBR1</italic>: c.*921T&#x0003e;G</td><td align="center">ss50394793</td><td align="center">4.3</td></tr><tr><td align="left"><sup><italic>a</italic></sup><italic>TGFBR1</italic>: c.*978G&#x0003e;A</td><td align="center">ss50394791</td><td align="center">1.1</td></tr><tr><td align="left"><sup><italic>a</italic></sup><italic>TGFBR1</italic>: c.*1004A&#x0003e;T</td><td align="center">ss50394792</td><td align="center">2.2</td></tr><tr><td align="left"><italic>TGFBR2</italic>: c.263+7A&#x0003e;G</td><td align="center">rs1155705</td><td align="center">10.8</td></tr><tr><td align="left"><sup><italic>a</italic></sup><italic>TGFBR2</italic>: c.263+17A&#x0003e;C</td><td align="center">ss50394787</td><td align="center">1.1</td></tr><tr><td align="left"><italic>TGFBR2</italic>: c.445-111A&#x0003e;G</td><td align="center">rs17026161</td><td align="center">2.2</td></tr><tr><td align="left"><italic>TGFBR2</italic>: c.445-4T&#x0003e;A</td><td align="center">rs11466512</td><td align="center">21.7</td></tr><tr><td align="left"><sup><italic>a</italic></sup><italic>TGFBR2</italic>: c.1149G&#x0003e;A</td><td align="center">ss50394788</td><td align="center">1.1</td></tr><tr><td align="left"><italic>TGFBR2</italic>: c.1157C&#x0003e;T</td><td align="center">rs2228048</td><td align="center">2.2</td></tr><tr><td align="left"><italic>TGFBR2</italic>: c.1515-91C&#x0003e;A</td><td align="center">rs2276767</td><td align="center">4.3</td></tr><tr><td align="left"><italic>TGFBR2</italic>: c.*327-329delAT</td><td align="center">rs4016180</td><td align="center">21.7</td></tr><tr><td align="left"><italic>TGFBR2</italic>: c.*747C&#x0003e;G</td><td align="center">rs11466531</td><td align="center">7.6</td></tr><tr><td align="left"><italic>TGFBR2</italic>: c.*835C&#x0003e;A</td><td align="center">rs17026332</td><td align="center">2.2</td></tr></tbody></table><table-wrap-foot><p><sup><italic>a</italic></sup>Novel SNPs accepted by dbSNP</p></table-wrap-foot></table-wrap><p>The distribution of genotypes was found to be in Hardy-Weinberg equilibrium for all SNPs in both case and control groups. No significant differences were observed in genotype and allele frequencies between case and control groups for any of the SNPs assessed (Table <xref ref-type="table" rid="T7">7</xref>). Logistic regression analysis for the clinical characteristics described in Table <xref ref-type="table" rid="T1">1</xref> did not reveal a significant association with any variant and diabetic nephropathy. Adjusted <italic>p </italic>values for these potential covariates are shown in Table <xref ref-type="table" rid="T8">8</xref>.</p><table-wrap position="float" id="T7"><label>Table 7</label><caption><p>Genotype and allele frequencies of selected SNPs in case and control groups. The five <italic>TGFB1 </italic>SNPs were selected on the basis of previous publications [23-27]. The remaining two <italic>TGFBR2 </italic>SNPs were selected from potentially functional SNPs identified through screening the gene as summarised in Table 1. Data are n (%)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>SNP</bold></td><td align="center"><bold>Genotype</bold></td><td align="center"><bold>Case</bold></td><td align="center"><bold>Control</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>Allele</bold></td><td align="center"><bold>Case</bold></td><td align="center"><bold>Control</bold></td><td align="center"><bold><italic>p </italic>value</bold></td></tr></thead><tbody><tr><td align="center"><bold><italic>TGFB1 </italic>-800G&#x0003e;A</bold></td><td align="center">GG</td><td align="center">188 (69.1)</td><td align="center">268 (73.0)</td><td align="center">0.56</td><td align="center">G</td><td align="center">454 (83.5)</td><td align="center">628 (85.6)</td><td align="center">0.30</td></tr><tr><td></td><td align="center">GA</td><td align="center">78 (28.7)</td><td align="center">92 (25.1)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">AA</td><td align="center">6 (2.2)</td><td align="center">7 (1.9)</td><td></td><td align="center">A</td><td align="center">90 (16.5)</td><td align="center">106 (14.4)</td><td></td></tr><tr><td align="center"><bold><italic>TGFB1 </italic>-509C&#x0003e;T</bold></td><td align="center">CC</td><td align="center">179 (65.8)</td><td align="center">245 (66.8)</td><td align="center">0.62</td><td align="center">C</td><td align="center">442 (81.3)</td><td align="center">595 (81.1)</td><td align="center">0.93</td></tr><tr><td></td><td align="center">CT</td><td align="center">84 (30.9)</td><td align="center">105 (28.6)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">TT</td><td align="center">9 (3.3)</td><td align="center">17 (4.6)</td><td></td><td align="center">T</td><td align="center">102 (18.7)</td><td align="center">139 (18.9)</td><td></td></tr><tr><td align="center"><bold><italic>TGFB1 </italic>+72InsC</bold></td><td align="center">- C</td><td align="center">221 (81.3)</td><td align="center">301 (82.0)</td><td align="center">0.88</td><td align="center">- C</td><td align="center">488 (89.7)</td><td align="center">663 (90.3)</td><td align="center">0.71</td></tr><tr><td></td><td align="center">+/- C</td><td align="center">46 (16.9)</td><td align="center">61 (16.6)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">+ C</td><td align="center">5 (1.8)</td><td align="center">5 (1.4)</td><td></td><td align="center">+C</td><td align="center">56 (10.3)</td><td align="center">71 (9.7)</td><td></td></tr><tr><td align="center"><bold><italic>TGFB1 </italic>+869T&#x0003e;C</bold></td><td align="center">TT</td><td align="center">151 (55.5)</td><td align="center">204 (55.6)</td><td align="center">0.86</td><td align="center">T</td><td align="center">403 (74.1)</td><td align="center">540 (73.6)</td><td align="center">0.84</td></tr><tr><td></td><td align="center">TC</td><td align="center">101 (37.1)</td><td align="center">132 (36.0)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">CC</td><td align="center">20 (7.4)</td><td align="center">31 (8.4)</td><td></td><td align="center">C</td><td align="center">141 (25.9)</td><td align="center">194 (26.4)</td><td></td></tr><tr><td align="center"><bold><italic>TGFB1 </italic>+915G&#x0003e;C</bold></td><td align="center">GG</td><td align="center">219 (80.5)</td><td align="center">298 (81.2)</td><td align="center">0.98</td><td align="center">G</td><td align="center">488 (89.7)</td><td align="center">661 (90.1)</td><td align="center">0.84</td></tr><tr><td></td><td align="center">GC</td><td align="center">50 (18.4)</td><td align="center">65 (17.7)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">CC</td><td align="center">3 (1.1)</td><td align="center">4 (1.1)</td><td></td><td align="center">C</td><td align="center">56 (10.3)</td><td align="center">73 (9.9)</td><td></td></tr><tr><td align="center"><sup><bold><italic>a</italic></bold></sup><bold><italic>TGFBR2 </italic>c.*747C&#x0003e;G</bold></td><td align="center">CC</td><td align="center">218 (90.5)</td><td align="center">287 (89.1)</td><td align="center">0.88</td><td align="center">C</td><td align="center">457 (94.8)</td><td align="center">606 (94.1)</td><td align="center">0.61</td></tr><tr><td></td><td align="center">CG</td><td align="center">21 (8.7)</td><td align="center">32 (9.9)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">GG</td><td align="center">2 (0.8)</td><td align="center">3 (0.9)</td><td></td><td align="center">G</td><td align="center">25 (5.2)</td><td align="center">38 (5.9)</td><td></td></tr><tr><td align="center"><sup><bold><italic>a</italic></bold></sup><bold><italic>TGFBR2 </italic>c.1149G&#x0003e;A</bold></td><td align="center">GG</td><td align="center">232 (96.3)</td><td align="center">317 (98.4)</td><td align="center">0.10</td><td align="center">G</td><td align="center">473 (98.1)</td><td align="center">639 (99.2)</td><td align="center">0.10</td></tr><tr><td></td><td align="center">GA</td><td align="center">9 (3.7)</td><td align="center">5 (1.6)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">AA</td><td align="center">0</td><td align="center">0</td><td></td><td align="center">A</td><td align="center">9 (1.9)</td><td align="center">5 (0.8)</td><td></td></tr></tbody></table><table-wrap-foot><p><sup><italic>a </italic></sup>272 cases and 367 controls were genotyped for TGFB1 SNPs with 241 cases and 322 controls genotyped for TGFBR2 variants.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T8"><label>Table 8</label><caption><p>Significance values following logistic regression analyses adjusting the association between diabetic nephropathy status and genotype for the listed potential confounders.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><italic>p </italic>value adjusted for:</bold></td><td align="center"><bold><italic>TGFB1 </italic>-800G&#x0003e;A</bold></td><td align="center"><bold><italic>TGFB1 </italic>-509C&#x0003e;T</bold></td><td align="center"><bold><italic>TGFB1 </italic>+72InsC</bold></td><td align="center"><bold><italic>TGFB1 </italic>+869T&#x0003e;C</bold></td><td align="center"><bold><italic>TGFB1 </italic>+915G&#x0003e;C</bold></td><td align="center"><bold><italic>TGFBR2 </italic>c.*747C&#x0003e;G</bold></td><td align="center"><bold><italic>TGFBR2 </italic>c.1149G&#x0003e;A</bold></td></tr></thead><tbody><tr><td align="left"><bold>-</bold></td><td align="center"><bold>0.56</bold></td><td align="center"><bold>0.62</bold></td><td align="center"><bold>0.89</bold></td><td align="center"><bold>0.86</bold></td><td align="center"><bold>0.98</bold></td><td align="center"><bold>0.88</bold></td><td align="center"><bold>0.11</bold></td></tr><tr><td align="left">Gender</td><td align="center">0.56</td><td align="center">0.45</td><td align="center">0.98</td><td align="center">0.92</td><td align="center">0.94</td><td align="center">0.88</td><td align="center">0.09</td></tr><tr><td align="left">Age at Diagnosis</td><td align="center">0.56</td><td align="center">0.61</td><td align="center">0.88</td><td align="center">0.86</td><td align="center">0.98</td><td align="center">0.88</td><td align="center">0.11</td></tr><tr><td align="left">Duration of Diabetes</td><td align="center">0.62</td><td align="center">0.69</td><td align="center">0.94</td><td align="center">0.94</td><td align="center">0.98</td><td align="center">0.56</td><td align="center">0.26</td></tr><tr><td align="left">HbA1c</td><td align="center">0.44</td><td align="center">0.63</td><td align="center">0.96</td><td align="center">0.80</td><td align="center">0.97</td><td align="center">0.86</td><td align="center">0.16</td></tr><tr><td align="left">BMI</td><td align="center">0.79</td><td align="center">0.72</td><td align="center">0.63</td><td align="center">0.79</td><td align="center">0.97</td><td align="center">0.22</td><td align="center">0.72</td></tr><tr><td align="left">Mean BP</td><td align="center">0.94</td><td align="center">0.93</td><td align="center">0.68</td><td align="center">0.99</td><td align="center">0.77</td><td align="center">0.31</td><td align="center">0.85</td></tr><tr><td align="left">All of the above</td><td align="center">0.36</td><td align="center">0.94</td><td align="center">0.93</td><td align="center">0.70</td><td align="center">0.96</td><td align="center">0.49</td><td align="center">0.95</td></tr></tbody></table></table-wrap><p>The level of observed LD between all genotyped variants within each gene, together with the raw |D'| and R<sup>2 </sup>scores are shown in the Figures (Figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>). The most common combinations of alleles observed 5' to 3' were GC-TG (49.4%); AC-TG (12.6%) and GT-CG (10.5%). In addition, we have identified a novel, rare variant at <italic>TGFB1: </italic>+728T&#x0003e;C (ss50394786).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Although |D'| values were not particularly large for TGFB1 markers (D' Plot), they were statistically significant. R<sup>2 </sup>measure, there was little correlation observed between the genotyped markers (R<sup>2 </sup>Plot). Further details are displayed in the descriptive shown tables below the LD Plots. D' is the value of D primer between the two loci; LOD is the log of the likelihood odds ration (a measure of confidence in the value of D'); R<sup>2 </sup>is the correlation coefficient between the two loci and CI low/CI high represent 95% confidence limits for D' where the minor allele frequency is greater than 5%.</p></caption><graphic xlink:href="1471-2350-8-5-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Strong linkage disequilibrium was not observed between the two genotyped markers for <italic>TGFBR2</italic>. Further details are displayed in the descriptive tables shown below the LD Plots.</p></caption><graphic xlink:href="1471-2350-8-5-2"/></fig></sec><sec><title>Discussion</title><p>There is considerable evidence supporting the role of <italic>TGFB1, TGFBR1 </italic>and <italic>TGFBR2 </italic>genes in the development of diabetic nephropathy. The functional importance of the TGF&#x003b2;1 protein is illustrated by the high degree of conservation observed across mammalian species. The TGF&#x003b2;1 gene comprises seven exons separated by relatively large introns [<xref ref-type="bibr" rid="B23">23</xref>]. Transcriptional regulation is complex with two major start sites identified at positions +1 and +271 [<xref ref-type="bibr" rid="B24">24</xref>]; polymorphic positions are typically reported relative to the first major transcription start site for this gene. We have assessed five SNPs, suggested to play a role in TGF&#x003b2;1 expression levels through their impact on regulatory regions of <italic>TGFB1 </italic>[<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>], for association with diabetic nephropathy. Genotype and allele frequencies were similar to those reported in other European populations, with a decreased frequency observed for the minor alleles of <italic>TGFB1: </italic>-509C&#x0003e;T and <italic>TGFB1: </italic>+869T&#x0003e;C compared to the ECTIM results [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. As illustrated by the LD Plots (Figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>), we observed low correlation between the genotyped SNPs. The |D'| values suggest that these SNPs have been separated by recombination, however as the magnitude of |D'| is biased for smaller sample sizes |D'|, lower values may be difficult to interpret. To further clarify the patterns of LD between genetic markers, we also examined R<sup>2 </sup>values as this measure of LD is not as susceptible to small sample sizes. It is important to note that |D'| is less than one only when all haplotypes are observed and that markers with disparate alleles frequencies will also affect these measures of LD. The patterns of LD indicate that all genotyped loci within each gene are not contained within a single haplotype block, thereby suggesting limited value in performing haplotype analysis &#x02013; i.e. the LD values suggest that these markers are not transmitted on a single haplotype, but are separated by recombination events. Our analysis suggests that all SNPs genotyped in this study are informative and the most common combinations of alleles observed are similar to those previously published [<xref ref-type="bibr" rid="B29">29</xref>]. Comparison of our data with Phase II, release 21 of the HapMap resource [<xref ref-type="bibr" rid="B30">30</xref>] supports our findings that the <italic>TGFB1 </italic>gene is located in a genomic region affected by a recombination hotspot. All recorded polymorphic sites in the HapMap CEPH (Utah residents with ancestry from northern and western Europe) population demonstrate poor correlation, suggesting that all should therefore be genotyped as 'tag' SNPs. None of the common variants genotyped for the <italic>TGFB1 </italic>gene in this study are recorded as polymorphic in the Phase II, release 21 HapMap Caucasian data set and the nearest polymorphic SNP is approximately 2 kb from our SNPs of interest.</p><p>We observed no significant differences in genotype or allele frequencies between case and control groups for any of the SNPs assessed. The <italic>TGFB1: </italic>+869T&#x0003e;C SNP has been associated with diabetic nephropathy in a Chinese population with type 2 diabetes [<xref ref-type="bibr" rid="B31">31</xref>], however our results do not support this finding for nephropathy in type 1 diabetes. The results from Wong and colleagues' smaller Chinese study (cases, n = 58; controls, n = 65), may be explained by a difference in genetic factors between type 1 and type 2 diabetes or differences between the Chinese and Irish populations.</p><p>Our study employed rigorous phenotypic criteria for inclusion of cases and controls. The annual incidence of diabetic nephropathy increases over the first fifteen to twenty years duration of type 1 diabetes, but after twenty-five years the absence of overt proteinuria makes the subsequent development of nephropathy unlikely [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. The present report utilised cases and controls that were well matched for prolonged duration of diabetes (cases mean duration = 26.9 &#x000b1; SD 8.3 years, control mean duration = 27.7 &#x000b1; SD 9.0years). Our results for <italic>TGFB1 </italic>are in accord with Ng and colleagues' study which also failed to find an association between the <italic>TGFB1: </italic>-800G&#x0003e;A, -509C&#x0003e;T, +869T&#x0003e;C or +915G&#x0003e;C polymorphisms and diabetic nephropathy in US Caucasians with type 1 diabetes [<xref ref-type="bibr" rid="B34">34</xref>]. This is in contrast to a larger study in UK Caucasians where a significant association (p = 0.027) was identified between <italic>TGFB1: </italic>+869T&#x0003e;C and diabetic nephropathy [<xref ref-type="bibr" rid="B35">35</xref>]. This UK study utilised the Golden Years cohort of type 1 diabetic individuals as a control population [<xref ref-type="bibr" rid="B31">31</xref>] with all the recruited subjects (n = 410) having a very long duration of type 1 diabetes (&#x0003e; 50 years). Although these individuals did not have renal failure due to diabetic nephropathy 29% were taking antihypertensive medication and 35.7% had evidence of micro- or macroalbuminuria [<xref ref-type="bibr" rid="B36">36</xref>]. These clinical features (antihypertensive medication and micro- or macroalbuminura) form distinct exclusion criteria from our own diabetic control group. Although our sample size has ~90% power to detect a doubling in the minor allele frequency in cases relative to controls (<italic>e.g</italic>. 10% vs. 5%), there is a need for a collaborative genotyping effort in larger sample collections to definitively determine the role of these SNPs in predisposition to diabetic nephropathy.</p><p>TGF&#x003b2; type I receptors form a heterodimeric complex with TGF&#x003b2; type II receptors and bind to TGF&#x003b2; to mediate many TGF&#x003b2; activities including regulation of cell proliferation, differentiation and extracellular matrix production. It has been recently reported that TGF&#x003b2;1-mediated epithelial-to-mesenchymal transition requires functional <italic>TGFBR2 </italic>[<xref ref-type="bibr" rid="B37">37</xref>]. Variants have been recorded for both <italic>TGFBR1 </italic>and <italic>TGFBR2 </italic>genes, however there is limited genomic information regarding their influence on diabetic nephropathy. <italic>TGFBR1 </italic>is composed of nine exons and maps to chromosome 9q33-q34 [<xref ref-type="bibr" rid="B38">38</xref>]. TGFBR2 is composed of seven exons and maps to 3p22 [<xref ref-type="bibr" rid="B39">39</xref>]. There are presently 409 validated SNPs recorded in dbSNP for these two genes (<italic>TGFBR1</italic>, n = 115; <italic>TGFBR2</italic>, n = 294; dbSNP, accessed 12/01/06). Due to the large number of reported SNPs and potential ethnic variation in SNP occurrence and frequency [<xref ref-type="bibr" rid="B40">40</xref>], we resequenced these genes in our population.</p><p>We prioritised screening of the protein coding regions of these genes to aid identification of potentially functional gene variants. We screened for variants directly affecting lariat regions, splice sites, exonic/intronic splice enhancers, signal sequences, protein coding sequence, polyadenylation signals and untranslated regions. It is possible that other variants may affect regulatory mechanisms, (promoter or enhancer elements, microRNA <italic>etc</italic>.) or that features such as post-translation modifications may affect these candidate genes and their subsequent protein activity. It is also possible that rare variants may play a role in susceptibility to diabetic nephropathy; however this study lacks sufficient sample numbers to definitively assess the role of rare variants in this disease. Five novel variants were identified in <italic>TGFBR1</italic>, of which none were at sufficient frequency to assess in this case-control collection. We have identified nine SNPs in <italic>TGFBR2</italic>. Two SNPs are located in exons (<italic>TGFBR2: </italic>c.1157C&#x0003e;T, <italic>TGFBR2: </italic>c.1149G&#x0003e;A) and one SNP in the 3' UTR which was found to be putatively functional (<italic>TGFBR2</italic>: c.*747C&#x0003e;G). Analysis of <italic>TGFBR2</italic>: c.*747C&#x0003e;G genotyping did not reveal a significant association with diabetic nephropathy. A microsatellite [AT]<sub>del </sub>was also identified in the 3' UTR of <italic>TGFBR2</italic>. <italic>TGFBR2: </italic>c.1157C&#x0003e;T in exon four was found in only one sample in the heterozygous state (MAF: 1.1%), and does not lead to a change in amino acid (aac &#x02192; aat = N<sup>389</sup>N). <italic>TGFBR2: </italic>c.1149G&#x0003e;A was found in only two samples (MAF: 2.2%), but leads to a non-synonymous change in amino acid (gtg &#x02192; atg = V<sup>387</sup>M) in the serine-threonine protein kinase active domain of the mature chain for TGF&#x003b2;R2 (PROSITE: PS00108; Pfam: PF00069, accessed 03/02/06). Genotyping <italic>TGFBR2: </italic>c.1149G&#x0003e;A did not reveal a significant association with diabetic nephropathy, however we did identify a doubling of the minor allele in cases (MAF: 1.9% in cases vs. 0.8% in controls). This finding may be due to the low frequency of minor allele, however our available sample numbers do not provide sufficient power to appropriately assess the association of this SNP with diabetic nephropathy. The search for causative variants for susceptibility to diabetic nephropathy is constrained by limited numbers of well-characterised, precisely phenotyped cases and controls, which represents a major challenge in the study of complex disease genetics. While the power to identify disease gene loci is influenced by many factors, the requirement for adequate samples sizes of stringently phenotyped individuals is critical to the success and validity of complex disease association studies. Our results warrant further investigations of rare variants, particularly the <italic>TGFBR2 </italic>exonic SNPs, provided the sample population is sufficiently powered to assess the association.</p></sec><sec><title>Conclusion</title><p>Although experimental evidence suggests TGF&#x003b2;1 blockade may be an important therapeutic target we were unable to identify any association between <italic>TGFB1 </italic>gene variants and diabetic nephropathy. In resequencing the genes we identified eight novel variants for <italic>TGFB1, TGFBR1 </italic>and <italic>TGFBR2 </italic>genes but did not detect significant association between any of the common SNPs and nephropathy in this Caucasian population with type 1 diabetes.</p></sec><sec><title>Abbreviations</title><p><italic>MAF</italic>: Minor allele frequency, <italic>SNP</italic>: Single nucleotide polymorphism, <italic>UTR</italic>: Untranslated region, <italic>TGF</italic>: Transforming growth factor</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AJM: Contributed to the conception and design of this study, carried out all resequencing and genotyping work, submitted all data to online repositories, drafted the manuscript and approved final manuscript.</p><p>DAS: Participated in study conception and design, critically reviewed the manuscript and approved final manuscript.</p><p>CCP: Performed all statistical analyses, contributed to data interpretation, critically reviewed the manuscript and approved final manuscript.</p><p>DS: Provided clinical supervision of patient recruitment in the Republic of Ireland, critically reviewed the manuscript and approved final manuscript.</p><p>APM: Participated in study conception and design, supervised recruitment of patients in Northern Ireland, contributed to data interpretation, co-wrote the manuscript and approved final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/5/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was funded by the Research and Development Office of Northern Ireland and the Health Research Board of Ireland. A. J. McK is supported by a Northern Ireland Kidney Research Fund postdoctoral fellowship.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="other"><person-group person-group-type="author"><collab>USRDS 2005</collab></person-group><article-title>United States Renal Data System, Annual Data Report (ADR) Atlas 2005</article-title><ext-link ext-link-type="uri" xlink:href="http://www.usrds.org/adr.htm"/></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seaquist</surname><given-names>ER</given-names></name><name><surname>Goetz</surname><given-names>FC</given-names></name><name><surname>Rich</surname><given-names>S</given-names></name><name><surname>Barbosa</surname><given-names>J</given-names></name></person-group><article-title>Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy</article-title><source>N Engl J Med</source><year>1989</year><volume>320</volume><fpage>1161</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">2710189</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>M</given-names></name><name><surname>Angelico</surname><given-names>MC</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><name><surname>Krolewski</surname><given-names>A</given-names></name></person-group><article-title>Familial factors determine the development of diabetic nephropathy in patients with IDDM</article-title><source>Diabetologia</source><year>1996</year><volume>39</volume><fpage>940</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">8858216</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krolewski</surname><given-names>M</given-names></name><name><surname>Eggers</surname><given-names>PW</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name></person-group><article-title>Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study</article-title><source>Kidney Int</source><year>1996</year><volume>50</volume><fpage>2041</fpage><lpage>2046</lpage><pub-id pub-id-type="pmid">8943488</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>MJ</given-names></name><name><surname>Beaty</surname><given-names>TH</given-names></name><name><surname>Liang</surname><given-names>KY</given-names></name></person-group><article-title>Can familial aggregation of disease be explained by familial aggregation of environmental risk factors?</article-title><source>Am J Epidemiol</source><year>1988</year><volume>127</volume><fpage>674</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">3341366</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>WB</given-names></name><name><surname>Andreoli</surname><given-names>TE</given-names></name></person-group><article-title>Transforming growth factor beta contributes to progressive diabetic nephropathy</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>7667</fpage><lpage>7669</lpage><pub-id pub-id-type="pmid">10884396</pub-id><pub-id pub-id-type="doi">10.1073/pnas.97.14.7667</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Noble</surname><given-names>NA</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name><name><surname>Border</surname><given-names>WA</given-names></name></person-group><article-title>Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>1814</fpage><lpage>1818</lpage><pub-id pub-id-type="pmid">7680480</pub-id><pub-id pub-id-type="doi">10.1073/pnas.90.5.1814</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>BB</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Ziyadeh</surname><given-names>FN</given-names></name></person-group><article-title>Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration</article-title><source>Kidney Int</source><year>1998</year><volume>54</volume><fpage>1107</fpage><lpage>1116</lpage><pub-id pub-id-type="pmid">9767526</pub-id><pub-id pub-id-type="doi">10.1046/j.1523-1755.1998.00119.x</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isaka</surname><given-names>Y</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Ueda</surname><given-names>N</given-names></name><name><surname>Kaneda</surname><given-names>Y</given-names></name><name><surname>Kamada</surname><given-names>T</given-names></name><name><surname>Imai</surname><given-names>E</given-names></name></person-group><article-title>Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney</article-title><source>J Clin Invest</source><year>1993</year><volume>92</volume><fpage>2597</fpage><lpage>2601</lpage><pub-id pub-id-type="pmid">8254017</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kopp</surname><given-names>JB</given-names></name><name><surname>Factor</surname><given-names>VM</given-names></name><name><surname>Mozes</surname><given-names>M</given-names></name><name><surname>Nagy</surname><given-names>P</given-names></name><name><surname>Sanderson</surname><given-names>N</given-names></name><name><surname>Bottinger</surname><given-names>EP</given-names></name><name><surname>Klotman</surname><given-names>PE</given-names></name><name><surname>Thorgeirsson</surname><given-names>SS</given-names></name></person-group><article-title>Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease</article-title><source>Lab Invest</source><year>1996</year><volume>74</volume><fpage>991</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">8667617</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziyadeh</surname><given-names>FN</given-names></name><name><surname>Hoffman</surname><given-names>BB</given-names></name><name><surname>Han</surname><given-names>DC</given-names></name><name><surname>Iglesias-De La Cruz</surname><given-names>MC</given-names></name><name><surname>Hong</surname><given-names>SW</given-names></name><name><surname>Isono</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>McGowan</surname><given-names>TA</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name></person-group><article-title>Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>8015</fpage><lpage>8020</lpage><pub-id pub-id-type="pmid">10859350</pub-id><pub-id pub-id-type="doi">10.1073/pnas.120055097</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>DC</given-names></name><name><surname>Hoffman</surname><given-names>BB</given-names></name><name><surname>Hong</surname><given-names>SW</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Ziyadeh</surname><given-names>FN</given-names></name></person-group><article-title>Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice</article-title><source>Am J Physiol Renal Physiol</source><year>2000</year><volume>278</volume><fpage>F628</fpage><lpage>F634</lpage><pub-id pub-id-type="pmid">10751224</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shankland</surname><given-names>SJ</given-names></name><name><surname>Pippin</surname><given-names>J</given-names></name><name><surname>Pichler</surname><given-names>RH</given-names></name><name><surname>Gordon</surname><given-names>KL</given-names></name><name><surname>Friedman</surname><given-names>S</given-names></name><name><surname>Gold</surname><given-names>LI</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Couser</surname><given-names>WG</given-names></name></person-group><article-title>Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy</article-title><source>Kidney Int</source><year>1996</year><volume>50</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">8807580</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Ikegaya</surname><given-names>N</given-names></name><name><surname>Fujigaki</surname><given-names>Y</given-names></name><name><surname>Matsui</surname><given-names>K</given-names></name><name><surname>Masaoka</surname><given-names>H</given-names></name><name><surname>Nagase</surname><given-names>M</given-names></name><name><surname>Hishida</surname><given-names>A</given-names></name></person-group><article-title>Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis</article-title><source>J Am Soc Nephrol</source><year>1998</year><volume>9</volume><fpage>2253</fpage><lpage>2261</lpage><pub-id pub-id-type="pmid">9848779</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YL</given-names></name><name><surname>Guh</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>ML</given-names></name><name><surname>Lai</surname><given-names>YH</given-names></name><name><surname>Tsai</surname><given-names>JH</given-names></name><name><surname>Hung</surname><given-names>WC</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Chuang</surname><given-names>LY</given-names></name></person-group><article-title>Interaction between high glucose and TGF-beta in cell cycle protein regulations in MDCK cells</article-title><source>J Am Soc Nephrol</source><year>1998</year><volume>9</volume><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">9527394</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isono</surname><given-names>M</given-names></name><name><surname>Mogyorosi</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>DC</given-names></name><name><surname>Hoffman</surname><given-names>BB</given-names></name><name><surname>Ziyadeh</surname><given-names>FN</given-names></name></person-group><article-title>Stimulation of TGF-beta type II receptor by high glucose in mouse mesangial cells and in diabetic kidney</article-title><source>Am J Physiol Renal Physiol</source><year>2000</year><volume>278</volume><fpage>F830</fpage><lpage>F838</lpage><pub-id pub-id-type="pmid">10807596</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>D</given-names></name><name><surname>Brissenden</surname><given-names>JE</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name></person-group><article-title>Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7</article-title><source>Somat Cell Mol Genet</source><year>1986</year><volume>12</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">3459257</pub-id><pub-id pub-id-type="doi">10.1007/BF01570787</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKnight</surname><given-names>AJ</given-names></name><name><surname>Savage</surname><given-names>DA</given-names></name><name><surname>Patterson</surname><given-names>CC</given-names></name><name><surname>Brady</surname><given-names>HR</given-names></name><name><surname>Maxwell</surname><given-names>AP</given-names></name></person-group><article-title>Resequencing of the characterised CTGF gene to identify novel or known variants and analysis of their association with diabetic nephropathy</article-title><source>J Hum Genet</source><year>2006</year><volume>51</volume><fpage>383</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">16501850</pub-id><pub-id pub-id-type="doi">10.1007/s10038-006-0368-7</pub-id></citation></ref><ref id="B19"><citation citation-type="other"><article-title>National Centre for Biotechnology Information</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov"/></citation></ref><ref id="B20"><citation citation-type="other"><article-title>Genome Variation Society recommendations for coding sequences</article-title><ext-link ext-link-type="uri" xlink:href="http://www.genomic.unimelb.edu.au/mdi/mutnomen/recs.html#DNA"/></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boreham</surname><given-names>C</given-names></name><name><surname>Savage</surname><given-names>JM</given-names></name><name><surname>Primrose</surname><given-names>D</given-names></name><name><surname>Cran</surname><given-names>G</given-names></name><name><surname>Strain</surname><given-names>J</given-names></name></person-group><article-title>Coronary risk factors in school-children</article-title><source>Arch Dis Child</source><year>1993</year><volume>68</volume><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">8481039</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bth457</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Rhee</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>van Tilburg</surname><given-names>A</given-names></name></person-group><article-title>Intron-exon structure of the human transforming growth factor-beta precursor gene</article-title><source>Nucleic Acids Res</source><year>1987</year><volume>15</volume><fpage>3188</fpage><lpage>3189</lpage><pub-id pub-id-type="pmid">3470709</pub-id><pub-id pub-id-type="doi">10.1093/nar/15.7.3188</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Glick</surname><given-names>A</given-names></name><name><surname>Sporn</surname><given-names>MB</given-names></name><name><surname>Roberts</surname><given-names>AB</given-names></name></person-group><article-title>Characterization of the promoter region of the human transforming growth factor-beta 1 gene</article-title><source>J Biol Chem</source><year>1989</year><volume>264</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">2909528</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cambien</surname><given-names>F</given-names></name><name><surname>Ricard</surname><given-names>S</given-names></name><name><surname>Troesch</surname><given-names>A</given-names></name><name><surname>Mallet</surname><given-names>C</given-names></name><name><surname>Generenaz</surname><given-names>L</given-names></name><name><surname>Evans</surname><given-names>A</given-names></name><name><surname>Arveiler</surname><given-names>D</given-names></name><name><surname>Luc</surname><given-names>G</given-names></name><name><surname>Ruidavets</surname><given-names>JB</given-names></name><name><surname>Poirier</surname><given-names>O</given-names></name></person-group><article-title>Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study</article-title><source>Hypertension</source><year>1996</year><volume>28</volume><fpage>881</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">8901839</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grainger</surname><given-names>DJ</given-names></name><name><surname>Heathcote</surname><given-names>K</given-names></name><name><surname>Chiano</surname><given-names>M</given-names></name><name><surname>Snieder</surname><given-names>H</given-names></name><name><surname>Kemp</surname><given-names>PR</given-names></name><name><surname>Metcalfe</surname><given-names>JC</given-names></name><name><surname>Carter</surname><given-names>ND</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name></person-group><article-title>Genetic control of the circulating concentration of transforming growth factor type beta1</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>93</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">9887336</pub-id><pub-id pub-id-type="doi">10.1093/hmg/8.1.93</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>MR</given-names></name><name><surname>El Gamel</surname><given-names>A</given-names></name><name><surname>Hasleton</surname><given-names>P</given-names></name><name><surname>Turner</surname><given-names>DM</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><article-title>Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation</article-title><source>Transplantation</source><year>1998</year><volume>66</volume><fpage>1014</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">9808485</pub-id><pub-id pub-id-type="doi">10.1097/00007890-199810270-00009</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lympany</surname><given-names>PA</given-names></name><name><surname>Avila</surname><given-names>JJ</given-names></name><name><surname>Mullighan</surname><given-names>C</given-names></name><name><surname>Marshall</surname><given-names>S</given-names></name><name><surname>Welsh</surname><given-names>KI</given-names></name><name><surname>du Bois</surname><given-names>RM</given-names></name></person-group><article-title>Rapid genotyping of transforming growth factor beta1 gene polymorphisms in a UK Caucasoid control population using the polymerase chain reaction and sequence-specific primers</article-title><source>Tissue Antigens</source><year>1998</year><volume>52</volume><fpage>573</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">9894857</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Syrris</surname><given-names>P</given-names></name><name><surname>Carter</surname><given-names>ND</given-names></name><name><surname>Metcalfe</surname><given-names>JC</given-names></name><name><surname>Kemp</surname><given-names>PR</given-names></name><name><surname>Grainger</surname><given-names>DJ</given-names></name><name><surname>Kaski</surname><given-names>JC</given-names></name><name><surname>Crossman</surname><given-names>DC</given-names></name><name><surname>Francis</surname><given-names>SE</given-names></name><name><surname>Gunn</surname><given-names>J</given-names></name><name><surname>Jeffery</surname><given-names>S</given-names></name><name><surname>Heathcote</surname><given-names>K</given-names></name></person-group><article-title>Transforming growth factor-beta1 gene polymorphisms and coronary artery disease</article-title><source>Clin Sci (Lond)</source><year>1998</year><volume>95</volume><fpage>659</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">9831690</pub-id></citation></ref><ref id="B30"><citation citation-type="other"><article-title>HapMap</article-title><ext-link ext-link-type="uri" xlink:href="http://www.HapMap.org"/><comment>accessed 12/10/06</comment></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Poon</surname><given-names>P</given-names></name><name><surname>Chow</surname><given-names>KM</given-names></name><name><surname>Szeto</surname><given-names>CC</given-names></name><name><surname>Cheung</surname><given-names>MK</given-names></name><name><surname>Li</surname><given-names>PK</given-names></name></person-group><article-title>Association of transforming growth factor-beta (TGF-beta) T869C (Leu10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese</article-title><source>Kidney Int</source><year>2003</year><volume>63</volume><fpage>1831</fpage><lpage>1835</lpage><pub-id pub-id-type="pmid">12675860</pub-id><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00919.x</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><name><surname>Krolewski</surname><given-names>AS</given-names></name></person-group><article-title>Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics</article-title><source>Diabetes Metab Rev</source><year>1995</year><volume>11</volume><fpage>287</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">8718493</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>CE</given-names></name></person-group><article-title>How to protect the kidney in diabetic patients: with special reference to IDDM</article-title><source>Diabetes</source><year>1997</year><volume>46</volume><fpage>S104</fpage><lpage>S111</lpage><pub-id pub-id-type="pmid">9285510</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>DP</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><name><surname>Krolewski</surname><given-names>AS</given-names></name></person-group><article-title>TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>41</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12500218</pub-id><pub-id pub-id-type="doi">10.1053/ajkd.2003.50011</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>WR</given-names></name><name><surname>Lympany</surname><given-names>PA</given-names></name><name><surname>Rippin</surname><given-names>JD</given-names></name><name><surname>Gill</surname><given-names>GV</given-names></name><name><surname>Barnett</surname><given-names>AH</given-names></name><name><surname>Bain</surname><given-names>SC</given-names></name><collab>Warren 3/UK GoKind Study Group</collab></person-group><article-title>The TGF-beta 1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes</article-title><source>Diabet Med</source><year>2005</year><volume>22</volume><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15606694</pub-id><pub-id pub-id-type="doi">10.1111/j.1464-5491.2005.01376.x</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bain</surname><given-names>SC</given-names></name><name><surname>Gill</surname><given-names>GV</given-names></name><name><surname>Dyer</surname><given-names>PH</given-names></name><name><surname>Jones</surname><given-names>AF</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>KE</given-names></name><name><surname>Smyth</surname><given-names>C</given-names></name><name><surname>Barnett</surname><given-names>AH</given-names></name></person-group><article-title>Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort)</article-title><source>Diabet Med</source><year>2003</year><volume>20</volume><fpage>808</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">14510860</pub-id><pub-id pub-id-type="doi">10.1046/j.1464-5491.2003.01029.x</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>SL</given-names></name><name><surname>Li</surname><given-names>AG</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Kulesz-Martin</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name></person-group><article-title>Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><fpage>1714</fpage><lpage>1723</lpage><pub-id pub-id-type="pmid">15937546</pub-id><pub-id pub-id-type="doi">10.1172/JCI24399</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Qumsiyeh</surname><given-names>M</given-names></name><name><surname>Benkhalifa</surname><given-names>M</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name></person-group><article-title>Assignment of human transforming growth factor-beta type I and type III receptor genes (TGFBR1 and TGFBR3) to 9q33-q34 and 1p32-p33, respectively</article-title><source>Genomics</source><year>1995</year><volume>28</volume><fpage>356</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">8530052</pub-id><pub-id pub-id-type="doi">10.1006/geno.1995.1157</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matthew</surname><given-names>S</given-names></name><name><surname>Murty</surname><given-names>VV</given-names></name><name><surname>Cheifetz</surname><given-names>S</given-names></name><name><surname>George</surname><given-names>D</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name><name><surname>Chaganti</surname><given-names>RS</given-names></name></person-group><article-title>Transforming growth factor receptor gene TGFBR2 maps to human chromosome band 3p22</article-title><source>Genomics</source><year>1994</year><volume>20</volume><fpage>114</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">8020936</pub-id><pub-id pub-id-type="doi">10.1006/geno.1994.1134</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Kawaida</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name></person-group><article-title>Ethnic differences in allele frequency of autoimmune-disease-associated SNPs</article-title><source>J Hum Genet</source><year>2005</year><volume>50</volume><fpage>264</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">15883854</pub-id><pub-id pub-id-type="doi">10.1007/s10038-005-0246-8</pub-id></citation></ref></ref-list></back></article> 